OBJECTIVES: Endometrial Cancer Health Outcomes Study in Argentina (ECHOS-A) is a real-world retrospective electronic medical chart study evaluating treatment patterns and health outcomes in patients with endometrial cancer (EC) affiliated to an insurance plan. Clinical characteristics of EC patients who received first-line (1L) platinum-based treatment (PBT) were described.

METHODS: Data from 2010–2019 were extracted from electronic medical charts. Index (proxy for diagnosis) was the first date of an EC-related health term or procedure/treatment. The study population included patients who received systemic treatment only and were classified as exposed to platinum if received any platinum drug as first systemic therapy. Frequency of platinum exposure by FIGO (International Federation of Gynecology and Obstetrics) stage was described (stages I/II and III/IV). Time until first platinum use, duration of treatment (DOT) (months), and frequency of carboplatin-paclitaxel (CP) use were described. Analyses are presented per FIGO stages groups.

RESULTS: 805 patients with EC were included. Among these, 198 were treated with systemic therapy, and from these, 73.7% (n=146) received PBT in 1L. Mean (standard deviation [SD]) age of this last group was 65.4 (10.4) years and 80.0% had a body mass index ≥25kg/m². Mean (SD) follow-up time was 35.8 (28.5) months. Mean (SD) time from index to first PBT was 6.1 (10.8) months. Most patients receiving PBT had FIGO stage information (n=123; 84.2%), in which 54.5% (n=67) were in stages I/II. Among patients receiving PBT, 72.6% (n=106) were treated with CP. Mean (SD) DOT among patients treated with PBT was 4.1 (4.2) months in stages I/II, and 3.5 (2.5) months in stages III/IV.

CONCLUSIONS: PBT, particularly CP, is a well-established option in 1L treatment for EC patients, even for earlier stages. Shorter DOT in advanced stages highlights the aggressive nature of advanced EC and the need for treatment options.